drugset
drugset / Trial / NCT04624958

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL

NCT04624958 ↗

Phase 2 Active not recruiting 42 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

This phase 2 trial studies the efficacy and safety of zanubrutinib plus rituximab followed by R-DHAOx (rituximab, dexamethasone, cytarabine and oxaliplatin) regimen then maintenance with zanubrutinib for newly-diagnosed Mantle Cell Lymphoma (MCL).

Timeline

Start
2020-12-01
Primary completion
2024-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule 1000 mg/m2 Intravenous
Subject Cytarabine Small molecule 2000 mg/m2 Intravenous
Subject Dexamethasone Small molecule 20 mg Intravenous
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Zanubrutinib Small molecule 160 mg Oral

Indications

mantle cell lymphoma